Abstract is: Joseph Schlessinger (born Josip Schlessinger; 26 March 1945) is a Yugoslav-born Israeli-American biochemist and biophysician. He is chair of the Pharmacology Department at Yale University School of Medicine in New Haven, Connecticut, as well as the founding director of the school's new Cancer Biology Institute. His area of research is signaling through tyrosine phosphorylation, which is important in many areas of cellular regulation, especially growth control and cancer. Schlessinger's work has led to an understanding of the mechanism of transmembrane signaling by receptor tyrosine kinases and how the resulting signals control cell growth and differentiation.
human | Q5 |
P2381 | Academic Tree ID | 22571 |
P268 | Bibliothèque nationale de France ID | 16957283b |
P8179 | Canadiana Name Authority ID | ncf11652500 |
P11496 | CiNii Research ID | 1140282266684825216 |
P646 | Freebase ID | /m/03clkd7 |
P213 | ISNI | 0000000022250773 |
P8189 | J9U ID | 987009748011205171 |
P244 | Library of Congress authority ID | n00122476 |
P2798 | Loop ID | 21321 |
P271 | NACSIS-CAT author ID | DA09440647 |
P5380 | National Academy of Sciences member ID | 3009519 |
P856 | official website | http://www.med.yale.edu/pharm/chairman/biography.htm |
P496 | ORCID iD | 0000-0002-5085-5969 |
P3368 | Prabook ID | 70807 |
P5504 | RISM ID | people/30033006 |
P214 | VIAF ID | 8625880 |
P10832 | WorldCat Entities ID | E39PBJw8Yt3xVymYPF3qjkrjG3 |
P512 | academic degree | Doctor of Philosophy | Q752297 |
P166 | award received | Dan David Prize | Q1158951 |
Keith R. Porter Lecture | Q1738081 | ||
BBVA Foundation Frontiers of Knowledge Award | Q6085042 | ||
Novartis-Drew Award | Q5119206 | ||
EMBO Membership | Q26268243 | ||
J. Allyn Taylor International Prize in Medicine | Q56072830 | ||
Fellow of the AACR Academy | Q61636373 | ||
P27 | country of citizenship | United States of America | Q30 |
Israel | Q801 | ||
P69 | educated at | Massachusetts Institute of Technology | Q49108 |
Hebrew University of Jerusalem | Q174158 | ||
P108 | employer | New York University | Q49210 |
Yale University | Q49112 | ||
P734 | family name | Schlessinger | Q7431702 |
Schlessinger | Q7431702 | ||
Schlessinger | Q7431702 | ||
P101 | field of work | biochemistry | Q7094 |
biophysics | Q7100 | ||
P735 | given name | Joseph | Q471788 |
Joseph | Q471788 | ||
P463 | member of | American Academy of Arts and Sciences | Q463303 |
National Academy of Sciences | Q270794 | ||
P1559 | name in native language | Joseph "Josip" Schlessinger | |
P106 | occupation | chemist | Q593644 |
researcher | Q1650915 | ||
biochemist | Q2919046 | ||
P21 | sex or gender | male | Q6581097 |
P937 | work location | Weizmann Institute of Science | Q4182 |
Q46847122 | 'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages |
Q28204617 | A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions |
Q31145317 | A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design |
Q28272683 | A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases |
Q28609913 | A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling |
Q41091475 | A point mutation at the ATP-binding site of the EGF-receptor abolishes signal transduction |
Q30476898 | A putative molecular-activation switch in the transmembrane domain of erbB2. |
Q24312845 | A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation |
Q35730035 | A structure-based model for ligand binding and dimerization of EGF receptors |
Q24310428 | A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1 |
Q35227172 | Activation and regulation of the insulin receptor kinase |
Q24323778 | Activation of Pyk2 by stress signals and coupling with JNK signaling pathway |
Q36530938 | Activation of insulin-epidermal growth factor (EGF) receptor chimerae regulates EGF receptor binding affinity |
Q41063499 | Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. |
Q30176542 | Activation of the JNK pathway is essential for transformation by the Met oncogene |
Q30159764 | Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli |
Q42069677 | Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase |
Q50097689 | Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. |
Q28626012 | All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor |
Q44111116 | All signaling is local? |
Q34812867 | Aryl Extensions of Thienopyrimidinones as Fibroblast Growth Factor Receptor 1 Kinase Inhibitors |
Q24298413 | Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells |
Q34113008 | Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases |
Q36435120 | Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions |
Q46968375 | Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction |
Q41758716 | Autoregulatory mechanisms in protein-tyrosine kinases |
Q30194769 | BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein |
Q41092861 | Biological activities of EGF-receptor mutants with individually altered autophosphorylation sites |
Q36251141 | Biologically active synthetic fragments of epidermal growth factor: localization of a major receptor-binding region |
Q29616451 | Catalytic specificity of protein-tyrosine kinases is critical for selective signalling |
Q24598357 | Cell signaling by receptor tyrosine kinases |
Q24597152 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma |
Q24302929 | Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors |
Q45165242 | Common and distinct elements in cellular signaling via EGF and FGF receptors |
Q73924701 | Conformation of an Shc-derived phosphotyrosine-containing peptide complexed with the Grb2 SH2 domain |
Q24317755 | Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynamin |
Q36693847 | Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization |
Q28574537 | Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways |
Q27730747 | Crystal structure at 2.2 A resolution of the pleckstrin homology domain from human dynamin |
Q24290400 | Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization |
Q33889677 | Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. |
Q27620743 | Crystal structure of the ARF-GAP domain and ankyrin repeats of PYK2-associated protein beta |
Q27654624 | Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2 |
Q22254157 | Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity |
Q40819546 | Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors |
Q28602870 | Data publication with the structural biology data grid supports live analysis |
Q36119294 | Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice |
Q112700471 | Design of protein-binding proteins from the target structure alone |
Q34390266 | Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities |
Q27658996 | Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling |
Q27659340 | Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-Based Virtual Screening |
Q24652600 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity |
Q37200035 | Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition |
Q36646666 | Early and multiple origins of metastatic lineages within primary tumors |
Q24529941 | Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface |
Q28143349 | Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src |
Q42025518 | Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells |
Q37028299 | Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas |
Q24607661 | Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma |
Q35549802 | FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis |
Q103802263 | FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho |
Q39855504 | FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma |
Q24531227 | FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. |
Q34314559 | FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts |
Q34373879 | FRS2α regulates Erk levels to control a self-renewal target Hes1 and proliferation of FGF-responsive neural stem/progenitor cells |
Q24306912 | Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro |
Q24611910 | GRB2 and phospholipase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation |
Q41739529 | Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity |
Q29618315 | Growth factor signaling by receptor tyrosine kinases |
Q54295628 | Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. |
Q54246457 | Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation |
Q24305821 | Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor |
Q24554522 | Identification of a new Pyk2 target protein with Arf-GAP activity |
Q22008764 | Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein |
Q24308600 | Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction |
Q54246428 | Identification of the Binding Site for Acidic Phospholipids on the PH Domain of Dynamin: Implications for Stimulation of GTPase Activity |
Q47652834 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer |
Q41024344 | Improved survival of patients with hypermutation in uterine serous carcinoma |
Q24306449 | Independent binding of peptide ligands to the SH2 and SH3 domains of Grb2 |
Q57947452 | Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cgamma1 |
Q36238299 | Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration |
Q24305380 | Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity |
Q59079619 | Insulin and antibodies against insulin receptor cap on the membrane of cultured human lymphocytes |
Q67916386 | Insulin-EGF receptor chimerae mediate tyrosine transphosphorylation and serine/threonine phosphorylation of kinase-deficient EGF receptors |
Q33584471 | Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae |
Q38307028 | Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. |
Q50938192 | JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules |
Q41092869 | Kinetic parameters of the protein tyrosine kinase activity of EGF-receptor mutants with individually altered autophosphorylation sites |
Q28637863 | Kit receptor dimerization is driven by bivalent binding of stem cell factor |
Q39807619 | Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway |
Q36637663 | Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma |
Q28646134 | Ligand-induced, receptor-mediated dimerization and activation of EGF receptor |
Q37161750 | Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms |
Q24306895 | Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal |
Q112575182 | Mechanism for the activation of the anaplastic lymphoma kinase receptor |
Q41846083 | Metabolic effects induced by epidermal growth factor (EGF) in cells expressing EGF receptor mutants |
Q37379877 | Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition |
Q39746901 | Mutations in different components of FGF signaling in LADD syndrome |
Q27632592 | Novel recognition mode between Vav and Grb2 SH3 domains |
Q54215704 | Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain. |
Q36612419 | Nuclear signaling by receptor tyrosine kinases: the first robin of spring |
Q34595942 | On the nature of low- and high-affinity EGF receptors on living cells |
Q57270016 | PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation |
Q40996433 | PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface |
Q40023501 | Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. |
Q42806503 | Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing |
Q38326603 | Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis |
Q28286087 | Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells |
Q30195382 | Presence of SH2 domains of phospholipase C gamma 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor |
Q34136306 | Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate |
Q24307776 | Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions |
Q28610859 | Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway |
Q35640945 | Pyk2 is required for neutrophil degranulation and host defense responses to bacterial infection |
Q27675701 | RAC1P29S is a spontaneously activating cancer-associated GTPase |
Q30540520 | Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development |
Q38193038 | Receptor tyrosine kinases: legacy of the first two decades |
Q41360988 | Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis |
Q37470078 | Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab |
Q40922726 | Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? |
Q40592846 | Regulation of signal transduction and signal diversity by receptor oligomerization |
Q57044276 | Reminiscences on the "Classic" 1976 FRAP Article in Biophysical Journal |
Q57947494 | Role of SH2-containing proteins in cellular signaling by receptor tyrosine kinases |
Q35178872 | SH2 and PTB domains in tyrosine kinase signaling |
Q30195496 | SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma |
Q41756065 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. |
Q103802284 | Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association |
Q37144170 | Scanning electron microscopy of cells and tissues under fully hydrated conditions |
Q54003856 | Scratching the surface with the PH domain. |
Q42832582 | Separate endocytic pathways of kinase-defective and -active EGF receptor mutants expressed in same cells |
Q57270013 | Shc Binding to Nerve Growth Factor Receptor Is Mediated by the Phosphotyrosine Interaction Domain |
Q58450633 | Signal Transduction by Epidermal Growth Factor Receptor |
Q27860624 | Signal transduction by receptors with tyrosine kinase activity |
Q24598414 | Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes |
Q44429540 | Signal transduction. Autoinhibition control |
Q35676722 | Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. |
Q30168465 | Solution structure of Grb2 reveals extensive flexibility necessary for target recognition |
Q34736828 | Solution structure of pleckstrin homology domain of dynamin by heteronuclear NMR spectroscopy |
Q27618450 | Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide |
Q77813531 | Solution structure of the SH2 domain of Grb2/Ash complexed with EGF receptor-derived phosphotyrosine-containing peptide |
Q39731307 | Spatial control of EGF receptor activation by reversible dimerization on living cells |
Q33777007 | Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain |
Q24314456 | Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation |
Q42613837 | Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells |
Q38309484 | Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond |
Q55045564 | Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain. |
Q22010544 | Structural basis for FGF receptor dimerization and activation |
Q27680371 | Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region |
Q24323270 | Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor |
Q27649204 | Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation |
Q28296195 | Structural basis for the activity of drugs that inhibit phosphodiesterases |
Q46702120 | Structural biology of receptor tyrosine kinase kit |
Q36463372 | Structural diversity and binding of FGF receptors |
Q27733279 | Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism |
Q27732194 | Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain |
Q37571141 | Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers |
Q50001768 | Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling |
Q35849511 | Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane |
Q36793907 | The Dark Side of Cell Signaling: Positive Roles for Negative Regulators |
Q38201344 | The EGFR family: not so prototypical receptor tyrosine kinases |
Q35926480 | The biochemical response of the heart to hypertension and exercise |
Q37635718 | The catalytic activity of the CD45 membrane-proximal phosphatase domain is required for TCR signaling and regulation |
Q28609622 | The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors |
Q35140672 | The docking protein FRS2α is a critical regulator of VEGF receptors signaling |
Q41296343 | The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway |
Q24799816 | The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway |
Q72658016 | The expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system |
Q42545786 | The genesis of Zelboraf: targeting mutant B-Raf in melanoma |
Q24307577 | The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor |
Q37370492 | The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations |
Q40949624 | The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases |
Q24322529 | The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site |
Q38600953 | The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer |
Q35729931 | The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function |
Q54246424 | Thermodynamic Studies of SHC Phosphotyrosine Interaction Domain Recognition of the NPXpY Motif |
Q48145602 | Tony Pawson (1952-2013). |
Q34245285 | Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains |
Q47835044 | Transmembrane signaling by receptor oligomerization |
Q41718624 | Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. |
Q33885990 | Two EGF molecules contribute additively to stabilization of the EGFR dimer |
Q24311075 | Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor |
Q27673339 | Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate |
Q24669865 | Tyrosine phosphorylation of Pyk2 is selectively regulated by Fyn during TCR signaling |
Q24336399 | Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation |
Q7204909 | Plexxikon | founded by | P112 |
azb | جوزف شلسینقر | wikipedia |
Joseph Schlessinger | wikipedia | |
Joseph Schlessinger | wikipedia | |
Persian (fa / Q9168) | جوزف شسیلینگر | wikipedia |
יוסף שלזינגר | wikipedia | |
Joseph Schlessinger | wikipedia | |
Шлессингер, Джозеф | wikipedia |
Search more.